Background/Objectives: We aimed to evaluate the temporal associations and heterogeneous patterns between the Beijing Diagnosis-Related Group (DRG) 2.0 payment reform and hospitalization costs and resource utilization among patients receiving major colorectal cancer (CRC) surgery and to explore hospital adaptive cost adjustment behaviors under bundled payment constraints. Methods: Utilizing inpatient data of 1232 colorectal cancer surgical patients from a Beijing hospital spanning January 2021 to October 2024, we adopted segmented regression interrupted time-series analysis (ITSA), with April 2022 defined as the policy intervention point. The analysis used total hospitalization expenses, itemized costs, cost composition proportions, and length of stay (LOS) as outcome indicators, conducted heterogeneity analysis, and applied seasonal autoregressive integrated moving average (SARIMA) counterfactual forecasting as a supplementary sensitivity check. All medical expenditures were inflation-adjusted based on Beijing’s medical consumer price index (CPI), with 2024 as the base year. Results: After DRG implementation, total hospitalization costs showed an immediate decrease of 13,111.73 CNY and a sustained monthly downward trend of 1312.60 CNY. Medical consumable fees were the main component associated with total-cost reduction, and their proportion declined immediately by 4.1 percentage points. LOS showed no abrupt immediate decline but shortened by 0.22 days per month over the post-reform period. Heterogeneous association patterns were observed across selected clinical and treatment subgroups. SARIMA counterfactual forecasting provided supplementary, directional sensitivity evidence for the primary outcomes and was interpreted cautiously for volatile sub-item expenditures. Conclusions: DRG 2.0 reform was associated with lower hospitalization costs and improved bed-turnover efficiency among CRC surgical patients, mainly through reductions in consumable expenditures.
Vascularized tumor organoid and tumor-on-chip models are increasingly used to examine treatment response, yet a weak therapeutic effect does not by itself identify the failed transport or biological step. Reduced efficacy may result from inadequate delivery, altered endothelial transport or signaling, stromal protection, impaired immune access or function, tumor-intrinsic resistance, or several processes acting together. A structured literature search and narrative synthesis were combined with a focused qualitative appraisal of 25 eligible primary studies to determine what evidence is needed to distinguish these explanations. Twenty-one studies included a relevant comparator, a mechanism-directed perturbation, and a functional readout; four directly tested a principal competing explanation, and three included rescue or reversal. Most studies therefore supported a contributory mechanism under the tested conditions rather than an exclusive causal attribution, leaving transport, stromal, immune, and tumor-intrinsic routes incompletely separated. The synthesis defines five candidate failed-step classes and specifies the comparisons, local-exposure or step-resolved measurements, perturbations, orthogonal readouts, and alternative tests needed for each. Mechanistic attribution is most secure when the proposed bottleneck is measured directly, manipulated experimentally, and distinguished from credible alternatives. Clinical application will additionally require context-of-use-specific evidence of analytical reproducibility, reference treatments, prespecified acceptance criteria, and association with clinically relevant outcomes.